CN101415436A - 重组恶性疟原虫裂殖子表面蛋白4和5及其用途 - Google Patents

重组恶性疟原虫裂殖子表面蛋白4和5及其用途 Download PDF

Info

Publication number
CN101415436A
CN101415436A CNA200680044019XA CN200680044019A CN101415436A CN 101415436 A CN101415436 A CN 101415436A CN A200680044019X A CNA200680044019X A CN A200680044019XA CN 200680044019 A CN200680044019 A CN 200680044019A CN 101415436 A CN101415436 A CN 101415436A
Authority
CN
China
Prior art keywords
msp4
polypeptide
msp5
antibody
reorganization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200680044019XA
Other languages
English (en)
Chinese (zh)
Inventor
S·朗埃克
H·波尔森
R·佩罗
F·纳托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Institut Pasteur
Original Assignee
NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATIONAL CENTER FOR SCIENTIFIC RESEARCH, Institut Pasteur filed Critical NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Publication of CN101415436A publication Critical patent/CN101415436A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNA200680044019XA 2005-11-23 2006-11-23 重组恶性疟原虫裂殖子表面蛋白4和5及其用途 Pending CN101415436A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73997305P 2005-11-23 2005-11-23
US60/739,973 2005-11-23

Publications (1)

Publication Number Publication Date
CN101415436A true CN101415436A (zh) 2009-04-22

Family

ID=38067607

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200680044019XA Pending CN101415436A (zh) 2005-11-23 2006-11-23 重组恶性疟原虫裂殖子表面蛋白4和5及其用途

Country Status (6)

Country Link
US (4) US8026354B2 (enExample)
EP (2) EP1954305B1 (enExample)
JP (2) JP2009517016A (enExample)
CN (1) CN101415436A (enExample)
CA (1) CA2630283A1 (enExample)
WO (1) WO2007060550A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102533678A (zh) * 2012-01-10 2012-07-04 特菲(天津)生物医药科技有限公司 一种间日疟红内期疫苗及其制备方法
CN101671654B (zh) * 2009-10-13 2012-11-07 黑龙江八一农垦大学 抗边缘无浆体msp5蛋白的单克隆抗体及其应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030161840A1 (en) * 1992-10-19 2003-08-28 Institut Pasteur Plasmodium falciparum antigens inducing protective antibodies
US8026354B2 (en) * 2005-11-23 2011-09-27 Institut Pasteur Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use
WO2011056216A1 (en) * 2009-11-05 2011-05-12 The United States Of America As Represented By The Secretary Of The Navy Plasmodium falciparum sporozoite and liver stage antigens
CU20100083A7 (es) * 2010-05-05 2012-06-21 Inst Finlay Tolerogenos adyuvados como vacuna de malaria
US20120244178A1 (en) * 2011-03-25 2012-09-27 Denise Doolan Plasmodium falciparum antigens
WO2015055772A1 (en) 2013-10-16 2015-04-23 Shirley Longacre Combination of plasmodium merozoite surface proteins msp4 and 1 and uses thereof
WO2015187652A1 (en) * 2014-06-02 2015-12-10 The Johns Hopkins University Malarial antigens derived from subtilisin-like protease 2 and vaccines and methods of use
US10622025B2 (en) 2018-06-05 2020-04-14 Seagate Technology Llc Carrierless storage chassis
US10354699B1 (en) 2018-06-05 2019-07-16 Seagate Technology Llc Carrierless storage chassis drive locking units
US11304328B2 (en) 2020-01-16 2022-04-12 Seagate Technology Llc Data storage retainer systems, methods, and devices

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
DE69034168T3 (de) 1989-03-21 2013-04-11 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
FR2681786A1 (fr) 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
FR2704145B1 (fr) 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
DE69939327D1 (de) 1998-11-02 2008-09-25 Curis Inc Funktionelle antagonisten von hedgehog-aktivität
AU1818200A (en) * 1998-11-05 2000-05-22 Daniel Carucci Chromosome 2 sequence of the human malaria parasite (plasmodium falciparum) and proteins of said chromosome useful in anti-malarial vaccines and diagnostic reagents
EP1267907A1 (en) * 2000-03-23 2003-01-02 Akzo Nobel N.V. Use of mia in immunotherapy
EP1529536A1 (en) * 2003-11-05 2005-05-11 Institut Pasteur Immunogenic composition having improved immunostimulation capacity
US20080260763A1 (en) * 2004-07-01 2008-10-23 The Regents Of The University Of California High Throughput Proteomics
US8026354B2 (en) * 2005-11-23 2011-09-27 Institut Pasteur Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101671654B (zh) * 2009-10-13 2012-11-07 黑龙江八一农垦大学 抗边缘无浆体msp5蛋白的单克隆抗体及其应用
CN102533678A (zh) * 2012-01-10 2012-07-04 特菲(天津)生物医药科技有限公司 一种间日疟红内期疫苗及其制备方法

Also Published As

Publication number Publication date
US20120115156A1 (en) 2012-05-10
CA2630283A1 (en) 2007-05-31
EP2329844A1 (en) 2011-06-08
US20130129766A1 (en) 2013-05-23
JP2012254082A (ja) 2012-12-27
JP2009517016A (ja) 2009-04-30
WO2007060550A2 (en) 2007-05-31
EP1954305B1 (en) 2012-09-19
US8026354B2 (en) 2011-09-27
EP1954305A2 (en) 2008-08-13
US20100092520A1 (en) 2010-04-15
WO2007060550A3 (en) 2008-01-03
US8350019B2 (en) 2013-01-08
US20080286805A1 (en) 2008-11-20
US8378087B2 (en) 2013-02-19

Similar Documents

Publication Publication Date Title
US8378087B2 (en) Recombinant Plasmodium falciparum merozoite surface proteins 4 and 5 and their use
Kennedy et al. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response
EP0815450B1 (en) Compounds and methods for the dectection of t. cruzi infection
Williamson Pfs230: from malaria transmission-blocking vaccine candidate toward function.
US5231168A (en) Malaria antigen
Wickramarachchi et al. Identification and characterization of a novel Plasmodium falciparum merozoite apical protein involved in erythrocyte binding and invasion
Singh et al. Antibodies raised against receptor-binding domain of Plasmodium knowlesi Duffy binding protein inhibit erythrocyte invasion
Kaneko et al. Disruption of the C-terminal region of EBA-175 in the Dd2/Nm clone of Plasmodium falciparum does not affect erythrocyte invasion
Child et al. Regulated maturation of malaria merozoite surface protein‐1 is essential for parasite growth
Pearce et al. Characterisation of two novel proteins from the asexual stage of Plasmodium falciparum, H101 and H103
EP0957937A1 (en) VACCINES, ANTIBODIES, PROTEINS, GLYCOPROTEINS, DNAS AND RNAS FOR PROPHYLAXIS AND TREATMENT OF $i(CRYPTOSPORIDIUM PARVUM) INFECTIONS
Bonnet et al. Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate
Srivastava et al. Specificity and inhibitory activity of antibodies to Plasmodium falciparum aldolase.
Black et al. MSP8 is a non-essential merozoite surface protein in Plasmodium falciparum
EP1526178B1 (en) MSP-3-like family of genes
Matsuoka et al. Induction of anti-malarial transmission blocking immunity with a recombinant ookinete surface antigen of Plasmodium berghei produced in silkworm larvae using the baculovirus expression vector system
CA2480786A1 (en) Recombinant p. falciparum merozoite protein-142 vaccine
EP2409987B1 (en) Ribosomal P protein complex from Plasmodium falciparum as antigen in vaccines against malaria
Lopera-Mesa et al. Plasmodium berghei merozoite surface protein-9: immunogenicity and protective efficacy using a homologous challenge model
EP1590368A1 (en) Compounds useful in the diagnosis and treatment of pregnancy-associated malaria
US20090324628A1 (en) Compounds useful in the diagnosis and treatment of malaria
PL178330B1 (pl) Sposób wytwarzania antygenu H11OD lub jego fragmentu o podobnej aktywności enzymatycznej i/lub antygenowej
VanBuskirk Partial Immunological and Functional Characterization of Plasmodium vivax Duffy Binding Protein
HK1075066B (en) Msp-3-like family of genes
Taechalertpaisarn et al. Biochemical and Functional Analysis of Two Plasmodium

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090422